Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix Pharmaceuticals released promising new clinical data for its BTX 1801 antimicrobial platform and a supporting presentation today.
The results demonstrate how synthetic cannabidiol kills resistant bacteria quickly and effectively – specifically Staphylococcus aureus (‘S.aureus’ or‘MRSA’ or ‘Golden Staph’), which greatly increases the risks of serious and life-threatening infections following surgery when it is carried in the nasal passage.
The following time-lapse videos clearly show how synthetic cannabidiol kills bacteria by rapidly disrupting the bacterial cytoplasmic membranes in as little as 10 minutes. In both videos, the bacteria are initially surrounded by a green fluorescent dye and exclusion of the dye means the bacteria are alive and well, while uptake of the dye means that the bacteria’s cell membrane has been disrupted and they are dying.
Time lapse video – S.aureus treated with methanol
This time lapse video shows S.aureus treated with 2.5% methanol (negative control) and grown at room temperature on an agarose pad containing 0.25µM SYTOX-Green. Bacteria are happy and rapidly multiplying over the 120 minutes, with no uptake of the dye.
Time lapse video – S.aureus treated with synthetic cannabidiol
This time lapse video shows S.aureus treated with with synthetic cannabidiol and grown at room temperature on an agarose pad containing 0.25µM SYTOX-Green. In contrast to the first video, bacteria immediately start to die, as evidenced by the rapid uptake of dye and disintegration of bacteria.
To learn more about our ongoing clinical research in the area of antimicrobial resistance, please subscribe to receive our latest news HERE.
One of the mysteries of COVID-19 is why it kills some patients while sparing others with similar health profiles.
The answer to this will not prove singular, of course. But research published in the prestigious medical journal The Lancet found that 50% of hospitalized patients who died of COVID-19 also had secondary bacterial infections. Some patients contracted these fatal infections from the very intensive care unit (ICU) ventilators that were intended to save them.
Read the full opinion editorial – written by President and CEO of Venatorx Pharmaceuticals, Inc. – on The Inquirer here.
Addressing antimicrobial resistance is a pressing priority for the largest health agencies in the world, so Botanix is optimistic in its efforts to proactively navigate these challenges.
Recruitment has today commenced in Perth for a Phase 2a study of Botanix’s antimicrobial platform product BTX 1801 to evaluate its safety, tolerability and efficacy for the prevention of surgical site infections.
The Phase 2a clinical study has been designed to evaluate two formulations of BTX 1801 to decolonise Staphylococcus aureus (Staph) and methicillin-resistant Staphylococcus aureus (MRSA or ‘Golden Staph’) from the nose of healthy adults. Nasal carriage of Staph and/or MRSA greatly increases the risks of serious and sometimes life-threatening infections following surgery, as patients essentially infect themselves.
Botanix is working with a team of specialist clinical investigators, led by Murdoch University’s Chair of Public Health and Chair of the Australia Group on Antimicrobial Resistance, Professor Geoffrey Coombs.
Read the Murdoch University news article here.
As humanity tallies the growing cost of Covid-19 in lives and capital, it must address the Grey Rhino threats posed by pathogenic bacteria. These are probable and impactful, but we neglect them despite their obviousness. Aided by modern humans’ mobility and by climate change, bacterial pathogens endanger everyone’s health. They are legion, varied, and constantly mutating. How can we best combat them?
Click HERE to read the article on Forbes.
The increased use of antibiotics to combat the Covid-19 pandemic will strengthen bacterial resistance and ultimately lead to more deaths during the crisis and beyond, the World Health Organization (WHO) has warned. WHO director general Tedros Adhanom Ghebreyesus said on Monday that a “worrying number” of bacterial infections were becoming increasingly resistant to the medicines traditionally used to treat them.
Click HERE to read the article on The Guardian.
According to the industry analysts covering BOT, breakeven is near. They anticipate the company to incur a final loss in 2021, before generating positive profits of AU$33m in 2022. Therefore, BOT is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, I calculated the rate at which BOT must grow year-on-year. It turns out an average annual growth rate of 96% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Click HERE to read the article on Simply Wall Street.